Novate Milanese, Italy

Germano D'Arasmo



Average Co-Inventor Count = 8.6

ph-index = 2

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2008-2016

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Germano D'Arasmo

Introduction

Germano D'Arasmo is a notable inventor based in Novate Milanese, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the development of proteasome inhibitors. With a total of six patents to his name, D'Arasmo's work has the potential to impact the treatment of various diseases, including cancer.

Latest Patents

One of D'Arasmo's latest patents focuses on proteasome inhibitors and methods of using the same. This invention provides boronic acid compounds, boronic esters, and compositions that can modulate apoptosis by inhibiting proteasome activity. The compounds and compositions developed can be utilized in methods for inducing apoptosis and treating diseases associated directly or indirectly with proteasome activity.

Career Highlights

Throughout his career, Germano D'Arasmo has worked with prominent companies in the pharmaceutical industry. Notable among these are Cephalon, Inc. and Millennium Pharmaceuticals Limited. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

D'Arasmo has collaborated with several professionals in his field, including Raffaella Bernardini and Alberto Bernareggi. These collaborations have likely enriched his research and development efforts, leading to advancements in his patented technologies.

Conclusion

Germano D'Arasmo's innovative work in the field of proteasome inhibitors showcases his commitment to advancing medical science. His contributions have the potential to significantly impact the treatment of serious diseases, highlighting the importance of his research and inventions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…